Brett T. Brinker
Experienced in IgG4-Related Disease

Dr. Brett T. Brinker

Hematology Oncology
145 Michigan Street Northeast, Suite 3100, 
Grand Rapids, MI 
On Staff At
Accepting New Patients
26 Years of Experience
Experienced in IgG4-Related Disease
145 Michigan Street Northeast, Suite 3100, 
Grand Rapids, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brett Brinker is a Hematologist Oncology provider in Grand Rapids, Michigan. Dr. Brinker has been practicing medicine for over 26 years and is rated as an Experienced provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are B-Cell Lymphoma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration. Dr. Brinker is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Emory University School Of Medicine, 2000
Residency
Emory University Hospital
Specialties
Hematology Oncology
Licenses
Internal Medicine in MI
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
Northwestern Memorial Hospital
Hospital Affiliations
Corewell Health Greenville Hospital
Corewell Health Reed City Hospital
Corewell Health Grand Rapids Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

The Cancer & Hematology Centers
145 Michigan Street Northeast, Suite 3100, Grand Rapids, MI 49503
Other Locations
The Cancer & Hematology Centers (Billing)
5800 Foremost Drive Southeast, Suite 300, Grand Rapids, MI 49546

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
Collection of Peripheral Blood From Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia for Measuring Baseline Ascorbic Acid Levels and Future Epigenetic Cancer Research
Collection of Peripheral Blood From Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia for Measuring Baseline Ascorbic Acid Levels and Future Epigenetic Cancer Research
Enrollment Status: Completed
Publish Date: October 03, 2019
Intervention Type: Other
View 2 Less Clinical Trials

6 Total Publications

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Journal: The New England journal of medicine
Published: October 16, 2024
Similar Doctors
Colin A. Hardin
Experienced in IgG4-Related Disease
Dr. Colin A. Hardin
Hematology Oncology | Hematology
Experienced in IgG4-Related Disease
Dr. Colin A. Hardin
Hematology Oncology | Hematology

The Cancer & Hematology Centers

145 Michigan Street Northeast, Suite 3100, 
Grand Rapids, MI 
 (7.0 miles away)
616-954-9800
Experience:
15+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Colin Hardin is a Hematologist and a Hematologist Oncology provider in Grand Rapids, Michigan. Dr. Hardin has been practicing medicine for over 15 years and is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Thrombocytopenia, Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Anemia, and Bone Marrow Aspiration. Dr. Hardin is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brinker's expertise for a condition
ConditionClose
    View All 17 Distinguished Conditions
    View All 38 Advanced Conditions
    View All 137 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile